Log In
Print
BCIQ
Print
Print this Print this
 

spebrutinib (AVL-292, CC-292)

  Manage Alerts
Collapse Summary General Information
Company Celgene Corp.
DescriptionCovalent small molecule Bruton's tyrosine kinase (Btk) inhibitor
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of ActionBruton's tyrosine kinase (Btk) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today